AbGenomics raises $9.6 mn for advancing its therapeutic antibodies for ... pharmabiz.com The company will use the raised amount to continue advancing its therapeutic antibodies for autoimmune diseases and cancers. AbGenomics' lead drug candidate AbGn-168H, a first-in-class humanized monoclonal antibody that specifically depletes chronic ... |
